SACUBITRIL; VALSARTAN | A213682 | ALEMBIC PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., et al 1 patentANDA 213682, 213605, 213748, 213646, 213671sacubitril/valsartan | D. Del. | 2022-10-24 | Terminated 2025-07-11 | — |
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited et al 4 patentsANDA 213682sacubitril/valsartan | D. Del. | 2020-01-17 | Terminated 2024-02-07 | — |
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited et al 4 patentsANDA 213682, 213728, 213689sacubitril/valsartan | D. Del. | 2019-10-24 | Terminated 2025-07-17 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.5859
per ea
Lowest NADAC/Unit
$0.5306
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62332055845SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 62332055860SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 62332055745SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 62332055760SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 62332055645SACUBITRIL-VALSARTAN 24-26 MG | $0.5306 | EA | Generic | — | 2026-06-17 |
| 62332055660SACUBITRIL-VALSARTAN 24-26 MG | $0.5306 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.